Celldex Therapeutics
CLDX
150 hedge funds and large institutions have $1.7B invested in Celldex Therapeutics in 2023 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 26 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 44
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
1.36% more ownership
Funds ownership: 104.86% → 106.22% (+1.4%)
4% less capital invested
Capital invested by funds: $1.78B → $1.7B (-$76.6M)
7% less funds holding
Funds holding: 161 → 150 (-11)
14% less call options, than puts
Call options by funds: $4.2M | Put options by funds: $4.89M
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$40.1M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$34.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$32M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$62.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$42M |
| 3 |
Morgan Stanley
New York
|
-$12M |
| 4 |
Jennison Associates
New York
|
-$8.53M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.92M |
CLDX Hedge Fund Activity: Q2 2023 in Review
150 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2023, worth a combined $1.7B — down 4.3% from $1.78B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CLDX and 17 opened new positions — a net loss of 9 holders — while 44 trimmed existing stakes and 61 added.
The largest buyer was Kynam Capital Management, adding an estimated $40.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $62.4M sold.
- 150 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2023, down from 161 in Q1 2023.
- Funds reported $1.7B of Celldex Therapeutics stock for Q2 2023, down 4.3% quarter-over-quarter.
- 17 funds opened new Celldex Therapeutics positions in Q2 2023 and 26 closed out, a net change of -9 holders.
- The largest Celldex Therapeutics buyer in Q2 2023 was Kynam Capital Management, an estimated $40.1M added.
- The largest Celldex Therapeutics seller in Q2 2023 was RA Capital Management, an estimated $62.4M sold.
Based on aggregated 13F filings for Q2 2023.